Ali Fattaey, Ph.D.

Dr. Fattaey has served as the company’s Director, President and Chief Executive Officer since June 2014. He joined the company in 2013 as President and Chief Operating Officer.

Previous experience:
President, Chief Executive Officer and Director, ACT Biotech, Inc.
Vice President, Research, Chiron Corporation (acquired by Novartis)
Chief Scientific Officer, Sagres Discovery (acquired by Chiron)
Vice President, Research, Onyx Pharmaceuticals – palbociclib (acquired by Amgen)
Director, EpiTherapeutics ApS (acquired by Gilead)
Director, Melanoma Therapeutics Foundation, a non-profit organization
Research Fellow, Medicine, Harvard Medical School, Massachusetts General Hospital
Ph.D. in Microbiology, Kansas State University

James Dentzer

Mr. Dentzer has served as the company’s CFO & Chief Operating Officer since March 2018. He joined the company in 2016 as CFO.

Previous experience:
Chief Financial Officer, Dicerna Pharmaceuticals
Chief Financial Officer, Valeritas
Chief Financial Officer, Amicus Therapeutics
VP & Corporate Controller, Biogen
Various Positions at DuPont, Kemper Financial Services and Bank of America Merrill Lynch (formerly Bank of Boston)
MBA, University of Chicago, and BA, Boston College

David Tuck, M.D.

Dr. Tuck has served as Curis’ Senior Vice President of Clinical and Translational Sciences since January 2016.  He joined the company in 2015 as Vice President of Clinical and Translational Sciences.

Previous experience:
Senior Medical Director, Oncology Translational Innovation, EMD Serono
Translational Physician, Ipilimumab and External Development of immune checkpoint inhibitors, Bristol-Myers Squibb
Associate Professor, Head of a Cancer Genomics and Bioinformatics Lab, Yale University
Associate Director, Yale Comprehensive Cancer Center
Director, Oncology Clinical Research (Taxol and novel anti-cancer compounds), Bristol-Myers Squibb
MD, University of Vermont and Board Certified in Internal medicine, Medical oncology and Hematology